Type 2 diabetes mellitus (DM2) is associated with insulin resistance and secretory dysfunction of the -cells. There is now experimental, epidemiological and clinical evidence suggesting that the immune system and inflammatory mediators are involved in the pathogenesis of DM2. The interest in regenerative therapeutics and cellular therapy for DM2 is motivated by the importance of preserving -cell mass and function. Cellular therapy with stem cells for glycemic control has been tested in experimental models for some years however, there are only a few published studies using this approach in humans. Although there are many obstacles to overcome before regenerative therapy becomes a real option to treat DM2, it may be an important strategy to attain metabolic control and prevent chronic complications in the future.
Diabetes mellitus; cell therapy; stem cell